文献速递神经免疫

Opicinumab治疗复发型多发性硬化的2期SYNERGY试验

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet Neurol · 2019-07-05

SYNERGY是一项随机双盲安慰剂对照剂量探索2期试验,纳入419例复发型多发性硬化患者,比较四种剂量opicinumab与安慰剂确认残疾改善的比例。

要点

  • 各剂量组确认残疾改善比例:3mg/kg 47%,10mg/kg 63%,30mg/kg 65%,100mg/kg 40%,安慰剂49%
  • 不良事件发生率药物组与安慰剂组均为85%,常见为流感样疾病、MS复发和头痛

核心结论

  • 研究未显示opicinumab相比安慰剂在复发型多发性硬化患者中有显著的线性剂量相关残疾改善。

研究设计与样本

  • 随机、双盲、安慰剂对照、剂量探索2期研究(SYNERGY),在12个国家72个中心进行。
  • 纳入419例18-58岁复发型多发性硬化患者(复发缓解型和伴复发的继发进展型)。
  • 按1:2:2:2:2随机分配至opicinumab 3、10、30、100 mg/kg或安慰剂,每4周静脉给药一次,所有患者每周肌注干扰素beta-1a作为背景抗炎治疗。
  • 主要终点为72周内达到确认残疾改善的参与者百分比,采用多组分终点(EDSS、T25FW、9HPT、3秒PASAT)。

主要发现

  • 72周确认残疾改善:安慰剂组45/91(49%),3mg/kg组21/45(47%),10mg/kg组59/94(63%),30mg/kg组59/91(65%),100mg/kg组36/91(40%)。
  • 常见不良事件(任何剂量opicinumab vs 安慰剂):流感样疾病140例(43%)vs 37例(40%),多发性硬化复发117例(36%)vs 30例(32%),头痛51例(16%)vs 23例(25%)。

关键数值与推荐

  • 主要终点确认残疾改善采用EDSS、T25FW、9HPT和3秒PASAT多组分评估。

临床怎么用

  • 当前证据不支持opicinumab用于复发型多发性硬化患者的常规治疗。
  • 需进一步研究探索特定亚组是否可能从最佳剂量opicinumab治疗中获益。

局限性

  • 原文未报告预设亚组分析的具体结果,仅提示需进一步研究亚组获益可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Opicinumab is a human monoclonal antibody against LINGO-1, an inhibitor of oligodendrocyte differentiation and axonal regeneration. Previous findings suggested that opicinumab treatment might enhance remyelination in patients with CNS demyelinating diseases. We aimed to assess the safety and efficacy of opicinumab in patients with relapsing multiple sclerosis. METHODS: We did a randomised, double-blind, placebo-controlled, dose-ranging, phase 2 study (SYNERGY) at 72 sites in 12 countries. Participants (aged 18-58 years) with relapsing multiple sclerosis (relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis with relapses) were randomised in a 1:2:2:2:2 ratio by an interactive voice and web response system to opicinumab 3 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg, or placebo. An identical volume of study drug was administered intravenously once every 4 weeks. All participants self-administered intramuscular interferon beta-1a as background anti-inflammatory treatment once a week. The primary endpoint was the percentage of participants achieving confirmed disability improvement over 72 weeks, which was a multicomponent endpoint measured by the Expanded Disability Status Scale, the Timed 25-Foot Walk, the Nine-Hole Peg Test, and the 3 s Paced Auditory Serial Addition Test. The primary endpoint was analysed under intention-to-treat principles. This study is registered at ClinicalTrials.gov, number NCT01864148. FINDINGS: Between Aug 13, 2013, and July 31, 2014, 419 patients were enrolled and randomly assigned either placebo (n=93) or opicinumab 3 mg/kg (n=45), 10 mg/kg (n=95), 30 mg/kg (n=94; one patient did not receive the assigned treatment), or 100 mg/kg (n=92). The last patient visit was on March 29, 2016. Confirmed disability improvement over 72 weeks was seen in 45 (49%) of 91 patients assigned to placebo, 21 (47%) of 45 assigned to opicinumab 3 mg/kg, 59 (63%) of 94 assigned to opicinumab 10 mg/kg, 59 (65%) of 91 assigned to opicinumab 30 mg/kg, and 36 (40%) of 91 assigned to opicinumab 100 mg/kg. A linear dose-response in the probability of confirmed disability improvement was not seen (linear trend test p=0·89). Adverse events occurred in 79 (85%) patients assigned placebo and in 275 (85%) assigned any dose of opicinumab. The most common adverse events of any grade in patients assigned any dose of opicinumab included influenza-like illness (140 [43%] with any dose of opicinumab vs 37 [40%] with placebo), multiple sclerosis relapses (117 [36%] vs 30 [32%]), and headache (51 [16%] vs 23 [25%]). Serious adverse events reported as related to treatment were urinary tract infection in one (1%) participant in the the placebo group, suicidal ideation and intentional overdose in one (1%) participant in the 30 mg/kg opicinumab group, bipolar disorder in one (1%) participant in the 100 mg/kg opicinumab group, and hypersensitivity in four (4%) participants in the 100 mg/kg opicinumab group. One patient in the opicinumab 30 mg/kg group died during the study due to a traffic accident, which was not considered related to study treatment. INTERPRETATION: Our findings did not show a significant dose-linear improvement in disability compared with placebo in patients with relapsing multiple sclerosis. Further studies are needed to investigate whether some subpopulations identified in the study might benefit from opicinumab treatment at an optimum dose. FUNDING: Biogen.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Cadavid D, Mellion M, Hupperts R, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019. PMID: 31285147. doi:10.1016/S1474-4422(19)30137-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。